What is MomeGalen® / Nasonex® (Mometason nasal)?
MomeGalen® and Nasonex® are nasal corticosteroid sprays with the active ingredient Mometasonfuroat. Mometason is one of the most commonly used nasal corticosteroids worldwide and is approved both for allergic rhinitis and for nasal polyps (Polyposis nasi).
Mometasonfuroate has a high local activity in the nasal mucosa with a very low systemic bioavailability (under 0.1% for nasal use). It is one of the safest nasal corticosteroids for long-term use.
MomeGalen® is the generic, Nasonex® is the original product. Both contain identically dosed active substance and are therapeutically equivalent.
Active Ingredients & Mechanism of Action
Active ingredient: Mometasonfuroat
Mometasonfuroate acts as a potent glucocorticoid in the nasal mucosa:
Active mechanism:
- Binding to intracellular glucocorticoid receptors
- inhibits the formation of inflammatory mediators (prostaglandins, leukotrienes)
- Reduces infiltration of eosinophiles, basophiles and mast cells
- Suppresses the allergic inflammatory reaction in the nasal mucosa
- Works swelling on the mucous membrane
Activation of nasal polyps:
- Reduces the size of nose polyps
- Improves nasal breathing
- Can delay an operation or make unnecessary
Initiation of action:
- First improvement frequently after 12 hours
- Clinically relevant effect after 1–2 days
- Full effect after 1–2 weeks of regular application
Who is it suitable for?
Mometason nasal is suitable for:
- Adults and young people from 12 years old with allergic rhinitis
- Children from 3 years (seasonal and perennial rhinitis, according to medical prescription)
- Adults aged 18 with nose polyps
- Seasonal and year-round allergies
Especially recommended at:
- Blocked nose as main symptoms
- Nose polyps with obstruction of nasal nude
- Long-term therapy (best safety profile among nasal corticosteroids)
- Children (aged from 3 years onwards – more experience than with Fluticasonfuroat)
Not suitable:
- Untreated nasal infections (arrows, bacteria)
- Nose bleeding or fresh nasal injuries
- Tuberculosis of the respiratory tract
Available Dosages
**Allergic rhinitis – adults and adolescents from 12 years:* *
- 2 spray taps per nostril once a day (= 200 μg total dose)
- Maintenance dose: 1 spray per nostril once a day (= 100 μg)
Allergic rhinitis – children 3–11 years:
- 1 spray per nostril once a day (= 100 μg)
Other polyps – Adults aged 18 and over
- 2 spray taps per nostril twice a day (= 400 μg)
- After improvement: 2 spray taps per nostril once a day
Available strength:
- 50 μg Mometasonfuroate per spray jet (140 spray rams per bottle)
Prophylactic:
- 2–4 weeks before expected pollen start
How to Take
Application:
- Nose gently
- Shake bottle
- Remove protective cap
- Insert spray opening into the nose hole (directed away from the vaginal wall)
- Once pumping, gently breathing through the nose
- Breathe through the mouth
Important notes:
- Pre-application: 10 times pump (to even spray mist)
- At > 14 days Non-use: 2 times pump
- Regular application for optimal effect
- Clean spray head weekly with warm water
- Do not spray towards the nose wall
Tips:
- left hand for right nostril, right hand for left nostril
- Head slightly forward
- For nasal polyps: Use consequently, even if improvement occurs
Contraindications
**Mometason nasal must not be used at:* *
- hypersensitivity to Mometasonfuroate or other components
- Untreated local infection of the nasal mucosa
Preview at:
- Active or latent tuberculosis
- Herpes simplex of eyes
- Systemic fungal infections
- Medical nose surgery or nose injury
- Long-term application in children (growth control)
- Simultaneous use of other corticosteroids (inhalative, dermal)
- Glaucoma or cataract in history
pregnant and breastfeeding: May only be applied after strict use-risk weighing. Systemic recording is minimal (< 0,1 %). For long-term application in pregnancy: Monitoring newborns for adrenal failure.
Possible Side Effects
Family (1–10 %):
- Nose bleeding (Epistaxis)
- Pharyngitis
- Headaches
** Occasionally (0.1-1 %):* *
- Burning or irritation in the nose
- Sneezing after application
- Flavour or odor disorders
Selten:
- Nose septumperforation (for long-term use, very rare)
- hypersensitivity reactions (angioedema, bronchospasm)
- Increased intraocular pressure, glaucoma, cataract (for long-term use)
Systemic side effects: Systemic corticoid effects are not to be expected when nasal application is intended. Mometason has a systemic bioavailability of less than 0.1%.
Children: Under long-term application: Regular monitoring of long-term growth recommended, although studies showed no significant growth impairment.
Interactions
Preview at:
- Ritonavir and strong CYP3A4 inhibitors (can theoretically increase systemic mometason exposure)
- Other corticosteroids (inhalative, oral, dermal – additive cortisolsuppression)
No relevant interaction with:
- Oral antihistamines (safe combination)
- Loratadin (examined in studies – no interaction)
- leukotriene antagonists (Montelukast)
- Swelling nasal sprays (short term)
** Due to the extremely low systemic bioavailability of Mometason nasal (< 0.1 %), systemic drug interactions are very unlikely.
Frequently Asked Questions
Similar Medications
Is MomeGalen® / Nasonex® (Mometason nasal) right for you?
A licensed doctor will review your information and issue a prescription if suitable. Discreet and secure.
Important Notice
This information does not replace medical advice. If you have questions about your health or the suitability of this medication, please consult a doctor or pharmacist.
Important Safety Information
This service operates under German pharmaceutical law (HWG). For risks and side effects, read the package leaflet and consult your doctor or pharmacist. All medications are dispensed from a licensed pharmacy in Germany.